Floatz logo

Rmc-6236

Pancreatic Ductal Adenocarcinoma

Tango Therapeutics, Inc.UNKNOWNPhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

279 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer
OHSU Knight Cancer Institute
Phase 2BB
Daraxonrasib
Revolution Medicines, Inc.
Phase 3BB
S-1
Genentech, Inc.
Phase 2BB
Ivospemin
Panbela Therapeutics, Inc.
Phase 2/3BB
Xaliplatin
Jonsson Comprehensive Cancer Center
Phase 4BB

View all 50 →

Same molecule, other indications

Rmc-6236 is also rated in:

digestive system cancerActive
CCC
Indicative · Phase 1/2
54 / 100
View asset →
pancreatic neoplasmActive
CCC
Indicative · Phase 3
50 / 100
View asset →
non-small cell lung carcinomaActive
CCC
Indicative · Phase 1/2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →